Tech Company Financing Transactions
OncoImmune Funding Round
On 9/10/2020, OncoImmune received $56 million in Series B financing from HM Capital, 3E Bioventures and GBA Capital.
Transaction Overview
Company Name
Announced On
9/10/2020
Transaction Type
Venture Equity
Amount
$56,000,000
Round
Series B
Investors
HM Capital (Lead Investor) (Robert Luo)
3E Bioventures (Karen Liu)
Proceeds Purpose
Oncoimmune will use the proceeds to support its novel therapeutic programs in late stage clinical trials and to expand its product pipeline.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
9430 Key West Ave. 113
Rockville, MD 20850
USA
Rockville, MD 20850
USA
Phone
Website
Email Address
Overview
Based in Rockville, Maryland, OncoImmune is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Medical Officer
Pan Zheng
Chief Operating Officer
Martin Devenport
Founder
Kun-Liang Guan
Founder
Ming You
President
Yang Liu
VP - Operations
Raymond Touomou
VP - Regulatory Affairs
Weng Tao
Browse more venture capital transactions:
Prev: 9/10/2020: Recursion Pharmaceuticals venture capital transaction
Next: 9/10/2020: Panther Labs venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs